BOTHELL, Wash.--(BUSINESS WIRE)--Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that data for the company’s novel visual cycle modulator, ACU-4429, a potential oral treatment for dry age-related macular degeneration (dry AMD), will be featured at the 8th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) being held in Rome, Italy from December 3 to 6, 2009. The data will be presented during the Retina: Dry AMD portion of the ISOPT program on Saturday, December 5, 2009 at 10:20 a.m. CET in Hall A of the Rome Cavalieri Hilton.
